Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

74.68
+2.323.21%
Post-market: 74.61-0.0700-0.09%18:59 EST
Volume:1.04M
Turnover:77.09M
Market Cap:6.00B
PE:8.35
High:75.00
Open:73.77
Low:72.64
Close:72.36
52wk High:87.50
52wk Low:35.95
Shares:80.29M
Float Shares:65.01M
Volume Ratio:0.83
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.94
EPS(LYR):-4.7276
ROE:-7740.12%
ROA:25.70%
PB:-38.50
PE(LYR):-15.80

Loading ...

PTC Therapeutics Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 05

PTC Therapeutics price target raised to $97 from $96 at BofA

TIPRANKS
·
Jan 30

Citi Keeps Their Hold Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Jan 30

PTC Therapeutics price target raised to $75 from $63 at TD Cowen

TIPRANKS
·
Jan 29

PTC Therapeutics Raised to Overweight From Equal-Weight by Barclays

Dow Jones
·
Jan 28

PTC Therapeutics assumed with Overweight from Equal Weight at Barclays

TIPRANKS
·
Jan 28

Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)?

Simply Wall St.
·
Jan 15

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Revolution Medicines (RVMD) and West Pharmaceutical Services (WST)

TIPRANKS
·
Jan 13

PTC Therapeutics: Sephience Outperformance and Votoplam De‑Risking Drive Upgraded Medium-Term Growth Outlook and Buy Rating

TIPRANKS
·
Jan 13

Wave of Insider Moves as PTC Therapeutics Leaders Cash In on Company Stock

TIPRANKS
·
Jan 13

Christine Marie Utter, SVP and Chief Accounting Officer, Reports Disposal of PTC Therapeutics Inc. Common Shares

Reuters
·
Jan 13

PTC Therapeutics Exec VP and CLO Mark Elliott Boulding Reports Sale of Common Shares

Reuters
·
Jan 13

PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook

TIPRANKS
·
Jan 13

BRIEF-Ptc Therapeutics Provides Update At J.P. Morgan Annual Healthcare Conference

Reuters
·
Jan 12

PTC Therapeutics forecasts 2026 product revenue of $700 to $800 million

Reuters
·
Jan 12

PTC Therapeutics Inc - Sephience Launch Continues With Unaudited Q4 Global Revenue of $92.5M

THOMSON REUTERS
·
Jan 12

PTC Therapeutics Inc - 2026 Product Revenue Guidance of $700 – 800M

THOMSON REUTERS
·
Jan 12

PTC Therapeutics Provides Update at J.p. Morgan Annual Healthcare Conference

THOMSON REUTERS
·
Jan 12

Wave of Insider Selling Sweeps Through PTC Therapeutics’ Executive Ranks

TIPRANKS
·
Jan 09

PTC Therapeutics CFO Pierre Gravier Reports Disposal of Common Shares

Reuters
·
Jan 09